SA PRO
Free Account
Themes
Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
OverviewIntelligenceChartsNews

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating
Buy
27 analysts·High coverage
85%
Rating Distribution
Strong Buy
00%
Buy
2385%
Hold
415%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 15% higher.

Bear Case
$441.00
-8%
Consensus
$549.31
+15%
Bull Case
$607.00
+27%
Price Range27 analysts
Low
Consensus
High
$441.00
$607.00
Current Target
Current Price
$477.71
Upside to Target
$71.60

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$19.32(19 analysts)
P/E30x
Current: 30.5x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+10.03%
EPS+14.70%
FY2028
Rev+10.10%
EPS+8.63%
FY2029
Rev+11.40%
EPS+19.74%

Earnings Surprises

Beat rate:58%(7/12 quarters)
Avg surprise:+1.9%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 2, 2026BMO Capital
Vertex (VRTX) PT Raised to $600 at BMO Capital
Target:$600.00
+23.1%from $487.57
Feb 17, 2026Canaccord Genuity
Vertex Pharmaceuticals price target raised to $441 from $411 at Canaccord
Target:$441.00
-10.3%from $491.47
Feb 17, 2026Barclays
Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays
Target:$607.00
+23.5%from $491.47
Feb 17, 2026H.C. Wainwright
Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright
Target:$591.00
+20.3%from $491.47
Feb 13, 2026Morgan Stanley
Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
Target:$570.00
+14.6%from $497.42
Feb 13, 2026Scotiabank
Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
Target:$558.00
+13.0%from $493.98
Feb 13, 2026RBC Capital
Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
Target:$541.00
+9.1%from $496.02
Feb 13, 2026Bernstein
Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
Target:$577.00
+16.0%from $497.21
Feb 13, 2026Cantor Fitzgerald
Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
Target:$590.00
+19.2%from $495.11
Feb 13, 2026Stifel Nicolaus
Vertex Pharmaceuticals price target raised to $466 from $445 at Stifel
Target:$466.00
+0.2%from $465.02
Feb 13, 2026H.C. Wainwright
Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright
Target:$518.00
+11.4%from $465.02
Jan 27, 2026Barclays
Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays
Target:$606.00
+27.8%from $474.17
Jan 26, 2026UBS
Vertex Pharmaceuticals price target raised to $545 from $535 at UBS
Target:$545.00
+15.0%from $474.09
Jan 23, 2026Evercore ISI
Vertex Pharmaceuticals price target raised to $530 from $475 at Evercore ISI
Target:$530.00
+13.0%from $469.11
Jan 22, 2026RBC Capital
Vertex upgraded to Outperform from Sector Perform at RBC Capital
Target:$546.00
+18.4%from $461.14
Jan 6, 2026UBS
Vertex Pharmaceuticals assumed with a Buy at UBS
Target:$535.00
+14.2%from $468.38
Dec 29, 2025Leerink Partners
Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink
Target:$525.00
+13.6%from $462.12
Dec 5, 2025Morgan Stanley
Vertex Pharmaceuticals price target raised to $564 from $516 at Morgan Stanley
Target:$564.00
+22.2%from $461.48
Dec 3, 2025Morgan Stanley
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
Target:$516.00
+19.1%from $433.15
Nov 4, 2025RBC Capital
Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital
Target:$415.00
-2.8%from $426.93
Nov 4, 2025Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
Target:$485.00
+13.5%from $427.30
Nov 4, 2025Stifel Nicolaus
Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel
Target:$445.00
+4.5%from $426.00
Nov 4, 2025Barclays
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays
Target:$414.00
-2.8%from $426.00
Oct 10, 2025Morgan Stanley
Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley
Target:$438.00
+5.8%from $413.93
Sep 25, 2025Leerink Partners
Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth
Target:$456.00
+19.4%from $381.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance